{"id":4391,"date":"2021-09-25T17:50:33","date_gmt":"2021-09-25T17:50:33","guid":{"rendered":"https:\/\/www.saince.com\/?p=4391"},"modified":"2023-04-28T09:41:29","modified_gmt":"2023-04-28T13:41:29","slug":"new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients","status":"publish","type":"post","link":"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/","title":{"rendered":"New PET imaging agent alters prostate cancer plan for more than 40% of patients"},"content":{"rendered":"<p dir=\"ltr\"><span style=\"font-weight: 400\">A recently developed PET imaging agent is earning praise following positive clinical trial results in men with high-risk prostate cancer.<\/span><\/p>\n<p dir=\"ltr\"><span style=\"font-weight: 400\">North Billerica, Massachusetts-based Lantheus presented early findings from a study at the recent American Urological Association virtual meeting. The PSMA-targeted agent\u2014piflufolastat F-18\u2014detected disease that had spread outside the prostate in nearly one-third of men.<\/span><\/p>\n<p dir=\"ltr\"><span style=\"font-weight: 400\">Additionally, an independent, retrospective review showed the imaging agent led to possible changes in care management strategy for 43.6% of patients, including decisions regarding surgery or radiation therapy.<\/span><\/p>\n<p dir=\"ltr\">Read more:\u00a0<a href=\"https:\/\/www.healthimaging.com\/topics\/molecular\/pet-agent-alters-prostate-cancer-plan\" class=\"broken_link\">https:\/\/www.healthimaging.com\/topics\/molecular\/pet-agent-alters-prostate-cancer-plan<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A recently developed PET imaging agent is earning praise following positive clinical trial results in men with high-risk prostate cancer. North Billerica, Massachusetts-based Lantheus presented early findings from a study at the recent American Urological Association virtual meeting. The PSMA-targeted agent\u2014piflufolastat F-18\u2014detected disease that had spread outside the prostate in nearly one-third of men. Additionally, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[],"class_list":["post-4391","post","type-post","status-publish","format-standard","hentry","category-radiology-updates"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.13 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>New PET imaging agent alters prostate cancer plan for more than 40% of patients -<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New PET imaging agent alters prostate cancer plan for more than 40% of patients -\" \/>\n<meta property=\"og:description\" content=\"A recently developed PET imaging agent is earning praise following positive clinical trial results in men with high-risk prostate cancer. North Billerica, Massachusetts-based Lantheus presented early findings from a study at the recent American Urological Association virtual meeting. The PSMA-targeted agent\u2014piflufolastat F-18\u2014detected disease that had spread outside the prostate in nearly one-third of men. Additionally, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-25T17:50:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-28T13:41:29+00:00\" \/>\n<meta name=\"author\" content=\"Raghu Vir\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Raghu Vir\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/\"},\"author\":{\"name\":\"Raghu Vir\",\"@id\":\"https:\/\/www.saince.com\/blog\/#\/schema\/person\/1f2d35babed92cc8da140a1e8098cc10\"},\"headline\":\"New PET imaging agent alters prostate cancer plan for more than 40% of patients\",\"datePublished\":\"2021-09-25T17:50:33+00:00\",\"dateModified\":\"2023-04-28T13:41:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/\"},\"wordCount\":105,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.saince.com\/blog\/#organization\"},\"articleSection\":[\"Radiology Updates\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/\",\"url\":\"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/\",\"name\":\"New PET imaging agent alters prostate cancer plan for more than 40% of patients -\",\"isPartOf\":{\"@id\":\"https:\/\/www.saince.com\/blog\/#website\"},\"datePublished\":\"2021-09-25T17:50:33+00:00\",\"dateModified\":\"2023-04-28T13:41:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.saince.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New PET imaging agent alters prostate cancer plan for more than 40% of patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.saince.com\/blog\/#website\",\"url\":\"https:\/\/www.saince.com\/blog\/\",\"name\":\"https:\/\/www.saince.com\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.saince.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.saince.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.saince.com\/blog\/#organization\",\"name\":\"Saince, Inc.\",\"url\":\"https:\/\/www.saince.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.saince.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.saince.com\/blog\/wp-content\/uploads\/2022\/11\/logo.png\",\"contentUrl\":\"https:\/\/www.saince.com\/blog\/wp-content\/uploads\/2022\/11\/logo.png\",\"width\":177,\"height\":50,\"caption\":\"Saince, Inc.\"},\"image\":{\"@id\":\"https:\/\/www.saince.com\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.saince.com\/blog\/#\/schema\/person\/1f2d35babed92cc8da140a1e8098cc10\",\"name\":\"Raghu Vir\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.saince.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b86bb9fa0a2c418a075287e457916b047d92fa95e18ae97c28b6be424e9ba817?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b86bb9fa0a2c418a075287e457916b047d92fa95e18ae97c28b6be424e9ba817?s=96&d=mm&r=g\",\"caption\":\"Raghu Vir\"},\"url\":\"https:\/\/www.saince.com\/blog\/author\/raghuvir\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New PET imaging agent alters prostate cancer plan for more than 40% of patients -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/","og_locale":"en_GB","og_type":"article","og_title":"New PET imaging agent alters prostate cancer plan for more than 40% of patients -","og_description":"A recently developed PET imaging agent is earning praise following positive clinical trial results in men with high-risk prostate cancer. North Billerica, Massachusetts-based Lantheus presented early findings from a study at the recent American Urological Association virtual meeting. The PSMA-targeted agent\u2014piflufolastat F-18\u2014detected disease that had spread outside the prostate in nearly one-third of men. Additionally, [&hellip;]","og_url":"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/","article_published_time":"2021-09-25T17:50:33+00:00","article_modified_time":"2023-04-28T13:41:29+00:00","author":"Raghu Vir","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Raghu Vir"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/#article","isPartOf":{"@id":"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/"},"author":{"name":"Raghu Vir","@id":"https:\/\/www.saince.com\/blog\/#\/schema\/person\/1f2d35babed92cc8da140a1e8098cc10"},"headline":"New PET imaging agent alters prostate cancer plan for more than 40% of patients","datePublished":"2021-09-25T17:50:33+00:00","dateModified":"2023-04-28T13:41:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/"},"wordCount":105,"commentCount":0,"publisher":{"@id":"https:\/\/www.saince.com\/blog\/#organization"},"articleSection":["Radiology Updates"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/","url":"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/","name":"New PET imaging agent alters prostate cancer plan for more than 40% of patients -","isPartOf":{"@id":"https:\/\/www.saince.com\/blog\/#website"},"datePublished":"2021-09-25T17:50:33+00:00","dateModified":"2023-04-28T13:41:29+00:00","breadcrumb":{"@id":"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.saince.com\/blog\/new-pet-imaging-agent-alters-prostate-cancer-plan-for-more-than-40-of-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.saince.com\/blog\/"},{"@type":"ListItem","position":2,"name":"New PET imaging agent alters prostate cancer plan for more than 40% of patients"}]},{"@type":"WebSite","@id":"https:\/\/www.saince.com\/blog\/#website","url":"https:\/\/www.saince.com\/blog\/","name":"https:\/\/www.saince.com","description":"","publisher":{"@id":"https:\/\/www.saince.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.saince.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.saince.com\/blog\/#organization","name":"Saince, Inc.","url":"https:\/\/www.saince.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.saince.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.saince.com\/blog\/wp-content\/uploads\/2022\/11\/logo.png","contentUrl":"https:\/\/www.saince.com\/blog\/wp-content\/uploads\/2022\/11\/logo.png","width":177,"height":50,"caption":"Saince, Inc."},"image":{"@id":"https:\/\/www.saince.com\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.saince.com\/blog\/#\/schema\/person\/1f2d35babed92cc8da140a1e8098cc10","name":"Raghu Vir","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.saince.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b86bb9fa0a2c418a075287e457916b047d92fa95e18ae97c28b6be424e9ba817?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b86bb9fa0a2c418a075287e457916b047d92fa95e18ae97c28b6be424e9ba817?s=96&d=mm&r=g","caption":"Raghu Vir"},"url":"https:\/\/www.saince.com\/blog\/author\/raghuvir\/"}]}},"_links":{"self":[{"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/posts\/4391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/comments?post=4391"}],"version-history":[{"count":1,"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/posts\/4391\/revisions"}],"predecessor-version":[{"id":4716,"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/posts\/4391\/revisions\/4716"}],"wp:attachment":[{"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/media?parent=4391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/categories?post=4391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/tags?post=4391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}